Findings

What do systematic reviews say?

3 questions · 3 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 33.3%Low 2 · 66.7%Moderate 0 · 0%High 0 · 0%

Bacillus Calmette‐Guérin (BCG) vs mitomycin

Time to recurrence

Bacillus Calmette‐Guérin (BCG) showed no clear difference in time to recurrence (absolute effect size estimates based on event… compared with mitomycin C (MMC) (low certainty).

1 finding from 1 review

Intravesical Bacillus Calmette‐Guérin versus mitomycin C for Ta and T1 bladder cancer 2020 · Cochrane Headline outcomes only
HR 0.88 [0.71, 1.09]
11 studies · 2616 participants
Low

Intravesically administered BCG combined with IFN‐α vs intravesically administered BCG alone

Recurrence · patients with non‐muscle invasive bladder cancer

It is very uncertain whether intravesically administered BCG combined with IFN‐α changes recurrence compared with intravesically administered BCG alone (very low certainty).

1 finding from 1 review

Intravesical Bacillus Calmette‐Guérin with interferon‐alpha versus intravesical Bacillus Calmette‐Guérin for treating… 2017 · Cochrane Headline outcomes only
RR 0.76 [0.44, 1.32]
4 studies · 925 participants
Very low

Intravesically administered BCG alternating with IFN‐α vs intravesically administered BCG alone

Time to recurrence · patients with non‐muscle invasive bladder cancer

Intravesically administered BCG alternating with IFN‐α may leads to higher time‐to‐recurrence compared with intravesically administered BCG alone (low certainty).

1 finding from 1 review

Intravesical Bacillus Calmette‐Guérin with interferon‐alpha versus intravesical Bacillus Calmette‐Guérin for treating… 2017 · Cochrane Headline outcomes only
HR 2.86 [1.98, 4.13]
1 study · 205 participants
Low